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OBJECTIVES: Antidepressants can cause undesirable drug-drug interactions when
taken concomitantly with certain medications. Elderly patients may be particularly 
vulnerable to antidepressant interactions due of slower metabolism and utilization 
of multiple pharmacotherapies. The objective of this study was to determine rates
of potential drug-drug interactions involving antidepressants in a geriatric population 
and their impact on prescription adherence. METHODS: Data were from the
MarketScan Medicare Database, a claims database from retirees with employer-
sponsored Medicare supplemental insurance. Subjects were age 65 years, new anti-
depressant users, and had a depression diagnosis between 7/1/2001–12/31/2006.
Potential drug-drug interactions involving at least one antidepressant and another drug
with overlapping days supplied were identiﬁ ed over the one year following antidepres-
sant initiation using MicroMedex DRUG-REAX software. Multinomial logistic 
regression and bivariate statistics were used to evaluate the association between
potential interactions and whether patients discontinued, reﬁ lled or switched their ﬁ rst 
antidepressant prescription. RESULTS: Among the 39,512 patients who met the inclu-
sion criteria, 25.4% had potential contraindicated or major interactions, 36.1% had 
moderate interactions, and 38.5% had minor or no interactions. Compared to the
moderate/minor/no interactions groups, the contraindicated/major group had a greater
prevalence of medical comorbidities and higher comorbidity indices (p  0.001).
Amitriptyline hydrochloride was involved in 19.1% of the potential contraindicated/
major interactions. Tramadol hydrochloride and oxycodone, opioid analgesics, were
the most common medications with contraindicated/major interactions. Presence of 
contraindicated/major and moderate interactions was associated with an increase
probability of switching to a different antidepressant of 23 and 11 percentage points, 
respectively (p  .001) and decreased probability of discontinuing of 3.5 and 2.5 per-
centage points (p  0.001), after controlling for age, gender, pre-period mental disor-
ders and medical comorbidities, antidepressant treatment type, and use of other 
psychotropic medications. CONCLUSIONS: Elderly antidepressant users frequently
use medications with the potential for interactions with their antidepressant medica-
tion. There is a need for antidepressants with improved interaction proﬁ les.
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OBJECTIVES: Patients prescribed a regimen of atypical antipsychotic medications face 
many challenges. Adherence and persistence rates are typically low. We investigated
determinants of adherence and persistence to second-generation antipsychotic medica-
tions (SGAs) for patients with schizophrenia and bipolar disorder, including ﬁ nancial
factors (patient cost-sharing and out-of-pocket burden) and formulary status.
METHODS: A retrospective study of patients aged 18–64 years with at least one SGA
claim, 24 months of continuous enrollment and employer-based coverage via large US
ﬁ rms in 2003–2006 (n  9714). The study initiation index date was deﬁ ned as the ﬁ rst
SGA ﬁ ll following a 12-month period without use of SGAs. Multivariate Cox propor-
tional hazards models were estimated for persistence to SGAs (using a 30-, 60- and
90-day gap in therapy) and multivariate cross-section/time-series models were esti-
mated for SGA adherence (PDC  80%). Explanatory variables included patient, plan,
and provider characteristics, health status, cost-sharing (prescription drug and medical) 
and time. An empirical measure of SGA formulary status was developed. RESULTS:
Over three quarters of patients (83%) discontinued SGA treatment and average per-
sistence until a 90-day gap was 184 days. Higher prescription drug and ofﬁ ce visit 
patient cost-sharing amounts were associated with shorter time on SGAs, especially 
when cost-sharing exceeded $40 per ﬁ ll or visit (95% conﬁ dence interval hazard ratio
for 90-day gap (1.01,1.15) prescription drug (1.00,1.24) ofﬁ ce visit) relative to cost-
sharing of $. Higher prescription drug cost-sharing and patient total (drug and
medical) out-of-pocket burden (measured in the previous 12 months) were associated 
with lower levels of adherence (both p  0.01). CONCLUSIONS: Even in a well-insured
patient population, beneﬁ t plan design factors can affect adherence and persistence to
SGAs for patients with schizophrenia and bipolar disorder. Insurers and plan managers
should take note of the prescription drug and medical plan design attributes that inﬂ u-
ence adherence to medications among this vulnerable patient group.
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OBJECTIVES: To investigate the relationship between compliance and ﬁ rst-year post-
treatment cost for patients with schizophrenia. METHODS: Commercial health plan 
data from July 1, 2003 to June 30, 2006 were used to identify patients with schizo-
phrenia who initiated treatment using a typical or atypical antipsychotic, a mood sta-
bilizer or an antidepressant. Episodes were divided into three categories: restarting 
treatment after a break in drug therapy 15 days with the drug used in the previous
episode; switching therapy with or without a break in treatment; and augmentation 
therapy. First observed episodes were excluded due to uncertainty concerning the 
patient’s prior treatment history. A total of 21,872 episodes were included in ordinary 
least squares (OLS) regression models of post-treatment cost as a function of alterna-
tive deﬁ nitions of compliance adjusting for age, gender, geographic region, drug use 
history, prior medical care use, schizophrenia diagnosis and co-morbid medical condi-
tions. RESULTS: Adding a second medication within one year is the key factor in the 
relationship between compliance and one-year costs. One year of uninterrupted 
therapy on the initial drug without adding a second medication increased drug costs 
by $3314, while reducing medical costs by $3919 (p  0.0001 for both estimates)
and total cost by $605 (p  0.05). One year of therapy on the initial drug augmented
with a second medication increased drug costs ($5062) and medical costs ($3477) 
compared to non-compliance (p  0.0001 for both estimates). One year of uninter-
rupted therapy on a second drug after terminating the initial therapy was associated 
with the highest costs: $3,955 for drugs and $8,902 for medical services (p  0.0001 
for all estimates). Analyses conducted separately by type of episode conﬁ rmed these
patterns of cost estimates. CONCLUSIONS: Compliance is associated with signiﬁ cant 
reductions in medical costs only if the patient is maintained on their initial drug
regimen. Changes in therapy are associated with higher medical costs.
PMH43
UNINTENDED CONSEQUENCES OF CURRENT ANTIDEPRESSANT USE 
IN A GERIATRIC POPULATION: THE BURDEN OF SIDE-EFFECTS ON
ADHERENCE AND COSTS
Mark TL1, Joish VN2, Hay JW3, Sheehan D4, Choi JC5, Johnston S1, Cao Z6
1Thomson Healthcare, Inc, Washington, DC, USA, 2Sanoﬁ -Aventis, Bridgewater, NJ, USA, 
3University of Southern California, Los Angeles, CA, USA, 4University of South Florida
College of Medicine, Tampa, FL, USA, 5Rutgers University, Piscataway, NJ, USA, 6Thomson
Healthcare, Inc, Cambridge, MA, USA
OBJECTIVES: The objective of this study was too characterize geriatric antidepressant
users’ rate of claims documented treatment-related side-effects, and their impact on
prescription-adherence and costs. METHODS: Data were from the MarketScan
Medicare Database, a de-identiﬁ ed health care database for retirees with employer-
sponsored Medicare supplemental insurance. Subjects age 65 years who were new 
antidepressant users with a depression diagnosis were identiﬁ ed between July 1, 2001-
December 31, 2006. Twelve commonly reported antidepressant side-effects were iden-
tiﬁ ed through ICD-9-CM diagnoses. Multinomial logistic regression was used to 
evaluate the effect of side-effects on adherence. RESULTS: A total of 39,512 treat-
ment-naïve antidepressants users were selected and compared to 1,144,481 non-users. 
Antidepressant users were slighter older than non-users (76.5 vs. 75.6 years, p 
0.001), more were female (63.2% vs. 52.5, p  0.001), and had higher prevalence of 
psychiatric, and non-psychiatric conditions. Approximately 5.5% (n  2214) of SSRI/
SNI users had diagnoses indicating side-effects within the ﬁ rst 30-days of treatment. 
Approximately 18% of new antidepressant users switched antidepressants, 23% dis-
continued, and 59% reﬁ lled after their ﬁ rst prescription ﬁ ll. The presence of a docu-
mented side-effect was associated with a 28.5% (4.7 percentage points) increase in 
the probability of switching and a 16.8% increase in the rate of discontinuation (3.7 
percentage points) (p  0.01). The average cost of medical and pharmaceutical treat-
ment for antidepressant side effects over the ﬁ rst month of treatment was approxi-
mately $336 (SD  $167). The cost of treating side-effects added $20.15 (1.8%) to
the total health care costs of the all antidepressant users during their ﬁ rst month after
antidepressant initiation. CONCLUSIONS: Antidepressant therapy in the elderly is 
associated with a signiﬁ cant level of side effects, which in turn is associated with lower
adherence, and greater cost of depression care. There is a need for an antidepressant 
with improved tolerability proﬁ le for the elderly to minimize non-adherence and eco-
nomic burden to payers.
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OBJECTIVES: To examine the impact of having a newly prescribed second generation 
anti-psychotic (SGA) claim rejected due to formulary restrictions on subsequent medi-
cation persistence to the SGAs. METHODS: A retrospective cohort study was con-
ducted using data from a national pharmacy beneﬁ t management company. Newly 
initiated antipsychotic users, aged 18–64 years who had a rejected SGA (aripiprazole, 
olanzapine, quetiapine, risperidone, ziprasidone) claim due to beneﬁ t reasons (step
